CMC Contrast

CMC Contrast AB (Lund, Sweden) is developing CMC 001 – an orphan contrast agent for liver imaging during MRI examinations. Today, patients suffering from severe chronic renal insufficiency or acute kidney injury are not eligible for use of existent contrast agents due to a risk of severe side effects. Accordingly, the diagnostics options available to this patient population are less efficient. CMC Contrast aims at providing better diagnostics tools for these patients to reduce the risk of making wrong treatment decisions.
Peter Benson, MSc

Managing Partner

Mobile: +45 40 80 48 69
Email Click here to contact